本帖最后由 老马 于 2012-1-13 21:20 编辑
; k9 I: d9 g; S4 z' s
, e2 M# a( M8 ~4 T爱必妥和阿瓦斯丁的比较2 n- i; O9 I" K Z
3 ^5 z" N/ i# Y3 S3 E. \http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
. y" }# X' w# K! ^! m5 I/ ?
9 I( ^+ K* d! a4 X, [! t
- u. R6 Q0 s0 q
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& [: A* }$ h( g* B6 g! h3 i9 ~
==================================================
+ C$ H; [4 B1 POverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ g# H5 u x$ qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.5 y, I) {* w& }4 L
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ D2 N4 ?' f' H! t+ J
|
显身卡
